SLC7A5 and breast carcinoma: The result suggested that LAT1 -inhibitor has been able to reduce the uptake of the prodrugs in human breast cancer (MCF-7) or retinal pigmented epithelial (ARPE-19) cells by 65–93% (Puris et al., 2017, 2019b).